ClinicalTrials.gg
Sign In
RecruitingNCT06295367Updated Oct 29, 2026

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

An interventional study of Best Practice and Financial Navigation in Malignant Solid Neoplasm, sponsored by ECOG-ACRIN Cancer Research Group. Recruiting at 391 sites in 3 countries. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by ECOG-ACRIN Cancer Research Group · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
760
Allocation
Randomized
Sex
All
01

Study summary

This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare patient-reported cost-related cancer care non-adherence at 12 months after completion of baseline survey between the enhanced usual care (EUC) and CostCOM study arms.

SECONDARY OBJECTIVES:

I. To compare patient-reported material financial hardship at 12 months after completion of baseline survey between the EUC and CostCOM study arms.

II. To compare patient-reported financial worry at 12 months after completion of baseline survey between the EUC and CostCOM study arms.

III. To compare patient-reported quality of life at 12 months after completion of baseline survey between the EUC and CostCOM study arms.

IV. To compare patient satisfaction with care at 12 months after completion of baseline survey between the EUC and CostCOM study arms.

EXPLORATORY OBJECTIVES:

I. To describe CostCOM (Arm B) patients and their provider experience with various implementation outcomes.

II. To assess accuracy of out-of-pocket estimates communicated with the CostCOM (Arm B) patients at part of the intervention with their reported actual out-of-pocket cost.

III. To compare neighborhood characteristics of patient participants versus (vs.) practice patient population.

IV. To assess patients' satisfaction with CostCOM in patients with Arm B. V. To assess patients' receipt of financial navigation via internal practice or external resources.

VI. To evaluate longitudinal changes in cost-related cancer care non-adherence, material hardship, financial worry, quality of life and satisfaction with care.

OUTLINE:

Non-patient participants: Participants complete surveys and participant in 1 on 1 in depth semi-structured interview over 20-30 minutes at 15-39 months after first patient enrollment.

Patients are randomized to 1 of 2 arms.

ARM A: Patients receive Patient Advocate Foundation (PAF) brochure describing financial navigation services.

ARM B: Patients receive usual financial care per practice standard of care and CostCOM financial counseling sessions over 1 hour within 30 days after enrollment and at 3, 6 and 12 months.

Patients are followed up within 12 months of study intervention completion.

02

Conditions studied

  • Malignant Solid Neoplasm
03

In context

Lead sponsor

ECOG-ACRIN Cancer Research Group is the lead sponsor of 122 studies on the registry; 16 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

Browse ECOG-ACRIN Cancer Research Group studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • NON-PATIENTS PARTICIPANTS: Participant must speak English
  • NON-PATIENTS PARTICIPANTS: Participant must be employed at National Cancer Institute Community Oncology Research Program (NCORP) site for at least six months
  • NON-PATIENTS PARTICIPANTS: Participant must be able to provide to participate in this study

  • NON-PATIENTS PARTICIPANTS: Participant must be one of the following:

    • A study coordinator with a role involving use of CostCOM intervention price transparency and financial navigation platform
    • A practice oncology provider (i.e., physician or mid-level), or
    • A practice financial counselor, social workers, financial navigators, or pharmacist who have provided care or been in contact (in the last 3 months) to a patient who was assigned to the CostCOM arm, and who completed the at least 6 month study follow-up
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be ≥ 18 years of age
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be within 120 days of a new diagnosis of any solid cancer of any stage at the time of Step 0
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have had their first medical oncology visit at the time of Step 0
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have initiated oral or intravenous (IV) cancer systemic therapy or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not have indolent cancer undergoing observation alone (i.e., active surveillance)
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not be receiving palliative or hospice care alone
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be undergoing curative surgery alone or radiation therapy alone. (Must be receiving systemic therapy), unless they are receiving systemic therapy
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must confirm that they intend to receive their care or monitoring at one of the participating NCORP practices

  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have the ability to understand and the willingness to sign a written informed consent document.

    • Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible

  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not have an (ECOG) performance status ≥ 3, OR

    • Patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in treatment clinical trials where cancer systemic therapy is provided at no cost to the patient

  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in EAQ221CD or S1912CD given financial navigation is offered as part of these two trials.

    • NOTE: If S1912CD is activated in a participating practice, S1912CD should be offered first to patients with cancer meeting eligibility criteria for S1912CD. Only if a patient is not eligible or not interested in participating in S1912CD, the EAQ222CD can be offered. For early stage cancer, EAQ222CD can be offered first given S1912CD does not enroll patients with early stage cancer

  • PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in other clinical trials where OOPC communication or financial navigation (i.e., professional guidance to identify financial assistance programs to alleviate cost of care) is being offered as part of the trial

    • NOTE: If a trial is offering financial counseling alone without financial navigation patients are allowed to co-enroll
    • NOTE: Gift cards for survey completion, or parking passes are not considered financial navigation
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must meet all the eligibility criteria for step 0
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have signed a written informed consent form
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have a completed baseline survey in ECOG American College of Radiology Imaging Network Systems for Easy Entry of Patient Reported Outcomes (EASEE-PRO) within 30 days of the date of OPEN registration and consent (step 0)
  • PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patients must have initiated their cancer treatment (i.e., IV or oral systemic therapy) either before or within 30 days of the date of OPEN registration and consent (step 0)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
760 participants (estimated)

Study arms

  • Active comparator
    ARM A (Enhanced usual care)

    Patients receive PAF brochure describing financial navigation services.

    Other: Best Practice · Other: Survey Administration

  • Experimental
    ARM B (CostCOM)

    Patients receive usual financial care per practice standard of care and CostCOM financial counseling sessions over 1 hour within 30 days after enrollment and at 3, 6 and 12 months.

    Other: Best Practice · Other: Financial Navigation · Other: Survey Administration

  • Experimental
    Non-patient participants: (interview)

    Non-patient participants complete surveys and participant in 1 on 1 in depth semi-structured interview over 20-30 minutes at 15-39 months after first patient enrollment.

    Other: Interview · Other: Survey Administration

Interventions

  • OtherBest Practice

    Receive PAF brochure describing financial navigation services

    Also known as: standard of care, standard therapy

  • OtherFinancial Navigation

    Receive CostCOM financial counseling

    Also known as: Financial Navigation Program

  • OtherInterview

    Participate in a 1 on 1 in-depth interview

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Cost-related cancer care non-adherence

    Cost-related cancer care non-adherence is defined as a positive response to any of the following due to costs: Delayed, forewent, stopped, or changed prescribed cancer medication; or delayed, forewent, or refused recommended cancer tests, or cancer office visits. Will be calculated as a report of non-adherence at any point up through the 12mo follow-up survey.

    Time frame: 12 months

Secondary outcomes

  1. Rate of Material Financial Hardship

    Rate of material hardship at each time point is a binary (yes/no) composite measure defined as a positive response to any of the following: (1) home sale, refinance or move to affordable rental, (2) loans, (3) reaching credit limits, and (4) bankruptcy because of your cancer care, or its treatment (adapted from Medical Expenditure Panel Survey).Material hardship at 12 months is measured as report of material hardship at any of the 3, 6 and 12 follow-ups.

    Time frame: at 12 months

  2. Patient-reported financial worry

    Measured by 12-item Comprehensive Score for Financial Toxicity (de Souza COST measure). Composite Scores range between 0-44 with higher the scores reflecting better the Financial Well-Being. Item 12 , an unscored summary item, will be used separately as a single item measure of financial worry. Mean score and changes in mean scores from baseline at each time point between the arms will be compared using two-sample t-tests.

    Time frame: At baseline and at 3, 6 and 12 months

  3. Patient-reported Quality of life - mental and physical health

    Measured using the 10-item Patient-Reported Outcomes Measurement Information System (PROMIS-10) version 1.2 Global Health. A T-score will be calculated for each of the global mental health and global physical health sections with a higher PROMIS T-score representing more of the concept being measured (mental/physical health). T-scores for the general population have a mean of 50 and a standard deviation (SD) of 10.Thus, a person who has T- scores of 60 for the Global Physical Health or Global Mental Health scales is one standard deviation better (more healthy) than the general population Mean score and changes in mean scores from baseline at each time point between the arms will be compared using two-sample t-tests.

    Time frame: At baseline and at 3, 6 and 12 months

  4. Patient-reported satisfaction with care at 12 months

    Satisfaction with the care will be measured using Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey questions. Composite items are rated on a scale of 0 to 10, with 0 being the worst and 10 being the best. Mean score and changes in mean scores from baseline at each time point between the arms will be compared using two-sample t-tests.

    Time frame: At baseline and at 3, 6 and 12 months

Other outcomes

  1. Out of pocket cost (OOPC) accuracy

    Mean absolute difference between OOPC estimates for the first cycle of therapy (as estimated by TailorMed Medical Incorporated) and the actual billed out of pocket (OOP) costs (as reported by patients based on their co-pays or medical bills).

    Time frame: At 3, 6 and 12 months

  2. Proportion of study patient participants that are of minority racial/ethnic background, and with public insurance will be measured and compared with that of practice patient population.

    Proportion of patients with specific characteristics, including racial, ethnic, payer mix, and neighborhood deprivation indices. Proportions will be compared between study participants and practice patient population.

    Time frame: Up to 12 months

  3. Patient reported satisfaction with intervention

    Qualitative interviews utilizing the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework was used to guide the evaluation questions and examine the effectiveness of the intervention and implementation outcomes. Participants describe their experience with various components of the CostCOM intervention: price transparency, financial navigation, and financial counseling, barriers and facilitators to participation, and feedback on what they liked and disliked about CostCOM, how it impacted their care, satisfaction with care, and what they would change to make it more helpful or engaging. The outcome measures are the proportion of subjects in the top 10 categories identified (5 for each like and dislike)

    Time frame: 39 months after enrollment of first study participant

  4. Receipt of financial navigation via internal practice or external resources

    Proportion of subjects receiving (at least 1 session) of financial navigation via study intervention, internal practice, or external resources. Receipt of financial counseling or financial assistance will be documented via treating clinic as extracted from medical records and intervention participants via reports from TailorMed Medical Incorporated

    Time frame: 12 months

  5. Evaluate longitudinal changes in Cost-related cancer care non-adherence, material hardship, financial worry, quality of life and satisfaction with care

    Cost-related cancer care outcomes of non-adherence, material hardship, financial worry, quality of life and satisfaction with care (reported above) are included in a Regression Model (GEE)

    Time frame: At baseline and at 3, 6 and 12 months

  6. longitudinal changes in cost-related cancer care non-adherence

    The effect of time (unitless Betas (slope)) will be estimated using a regression model (stage-stratified GEE analyses) for the Cost-related Outcomes non-adherence, material hardship, financial worry, quality of life, and satisfaction with care Regression intervention parameter (COSTCOM v EUC) will use EUC as the reference category. Cost-related cancer care non-adherence is defined as a positive response to any of the following due to costs: Delayed, forewent, stopped, or changed prescribed cancer medication; or delayed, forewent, or refused recommended cancer tests, or cancer office visits

    Time frame: At baseline, 3, 6 and 12 months

  7. longitudinal changes in cost-related cancer care material hardship

    The effect of time (unitless Betas (slope)) will be estimated using a regression model (stage-stratified GEE analyses) for the Cost-related Outcomes non-adherence, material hardship, financial worry, quality of life, and satisfaction with care Regression intervention parameter (COSTCOM v EUC) will use EUC as the reference category. Material hardship is a binary (yes/no) composite measure defined as a positive response to any of the following: (1) home sale, refinance or move to affordable rental, (2) loans, (3) reaching credit limits, and (4) bankruptcy because of your cancer care, or its treatment (adapted from Medical Expenditure Panel Survey).

    Time frame: At baseline, 3, 6 and 12 months

  8. longitudinal changes in cost-related cancer care financial worry

    The effect of time (unitless Betas (slope)) will be estimated using a regression model (stage-stratified GEE analyses) for the Cost-related Outcomes non-adherence, material hardship, financial worry, quality of life, and satisfaction with care Regression intervention parameter (COSTCOM v EUC) will use EUC as the reference category. Financial Worry measured by the 12-item Comprehensive Score for Financial Toxicity (de Souza COST measure). Composite Scores range between 0-44 with higher the scores reflecting better the Financial Well-Being. Item 12 , an unscored summary item, will be used separately as a single item measure of financial worry. Mean score and changes in mean scores from baseline at each time point between the arms will be compared using two-sample t-tests.

    Time frame: At baseline, 3, 6 and 12 months

  9. longitudinal changes in cost-related cancer care quality of life

    The effect of time (unitless Betas (slope)) will be estimated using a regression model (stage-stratified GEE analyses) for the Cost-related Outcomes non-adherence, material hardship, financial worry, quality of life, and satisfaction with care Regression intervention parameter (COSTCOM v EUC) will use EUC as the reference category. Quality of life is measured using the 10-item Patient-Reported Outcomes Measurement Information System (PROMIS-10) ver 1.2 Global Health. A T-score will be calculated for each global mental health and global physical health sections with a higher PROMIS T-score representing more of the concept being measured (mental/physical health). T-scores for the general population have a mean of 50 and a standard deviation (SD) of 10.Thus, a person who has T- scores of 60 for the Global Physical Health or Global Mental Health scales is one standard deviation better (more healthy) than the general population Mean score and changes in mean scores from base

    Time frame: At baseline, 3, 6 and 12 months

  10. longitudinal changes in cost-related cancer care satisfaction with care

    The effect of time (unitless Betas (slope)) will be estimated using a regression model (stage-stratified GEE analyses) for the Cost-related Outcome Satisfaction with care Regression intervention parameter (COSTCOM v EUC) will use EUC as the reference category. Satisfaction with the care is measured using the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey questions. Composite items are rated on a scale of 0 to 10, with 0 being the worst and 10 being the best.

    Time frame: At baseline, 3, 6 and 12 months

07

Study locations

363 of 391 sites recruiting

Showing the first 100 of 391 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Sadigh G, Duan F, Gareen IF, Hancock J, Sicks JD, Hawley S, Shankaran V, Torres M, Wagner LI, Carlos RC. Effectiveness of out-of-pocket cost COMmunication and financial navigation (CostCOM) in cancer patients: Study protocol for ECOG-ACRIN EAQ222CD. Contemp Clin Trials. 2025 Jun;153:107889. doi: 10.1016/j.cct.2025.107889. Epub 2025 Mar 25. PubMed 40147544 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2024 (actual). Primary completion is estimated for Nov 2027, 43 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Dec 2027, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Mar 6, 2024
StartActual
Apr 10, 2024
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 30, 2027was Nov 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 29, 2026
Sites
391 sites changed recruiting status (363 now recruiting, 27 now suspended, …)
Show 391 sites
  • Anchorage Associates in Radiation Medicine · Anchorage, United Statesno status→Recruiting
  • Alaska Breast Care and Surgery LLC · Anchorage, United Statesno status→Recruiting
  • Alaska Oncology and Hematology LLC · Anchorage, United Statesno status→Recruiting
  • Alaska Women's Cancer Care · Anchorage, United Statesno status→Recruiting
  • Katmai Oncology Group · Anchorage, United Statesno status→Recruiting
  • Providence Alaska Medical Center · Anchorage, United Statesno status→Recruiting
  • Fairbanks Memorial Hospital · Fairbanks, United Statesno status→Recruiting
  • Kingman Regional Medical Center · Kingman, United Statesno status→Recruiting
  • Mercy Hospital Fort Smith · Fort Smith, United Statesno status→Recruiting
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, United Statesno status→Recruiting
  • CARTI Cancer Center · Little Rock, United Statesno status→Recruiting
  • PCR Oncology · Arroyo Grande, United Statesno status→Recruiting
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United Statesno status→Recruiting
  • Contra Costa Regional Medical Center · Martinez, United Statesno status→Recruiting
  • Providence Queen of The Valley · Napa, United Statesno status→Recruiting
  • Providence Medical Foundation - Santa Rosa · Santa Rosa, United Statesno status→Recruiting
  • Providence Santa Rosa Memorial Hospital · Santa Rosa, United Statesno status→Recruiting
  • BASS Medical Group - Lennon · Walnut Creek, United Statesno status→Recruiting
  • Rocky Mountain Cancer Centers-Aurora · Aurora, United Statesno status→Recruiting
  • Boulder Community Foothills Hospital · Boulder, United Statesno status→Recruiting
  • Rocky Mountain Cancer Centers-Boulder · Boulder, United Statesno status→Recruiting
  • Rocky Mountain Cancer Centers - Centennial · Centennial, United Statesno status→Recruiting
  • The Women's Imaging Center · Denver, United Statesno status→Recruiting
  • Colorado Blood Cancer Institute · Denver, United Statesno status→Recruiting
  • Presbyterian - Saint Lukes Medical Center - Health One · Denver, United Statesno status→Recruiting
  • Rocky Mountain Cancer Centers-Midtown · Denver, United Statesno status→Recruiting
  • Rocky Mountain Cancer Centers-Rose · Denver, United Statesno status→Recruiting
  • Mountain Blue Cancer Care Center - Swedish · Englewood, United Statesno status→Suspended
  • Rocky Mountain Cancer Centers - Swedish · Englewood, United Statesno status→Recruiting
  • The Melanoma and Skin Cancer Institute · Englewood, United Statesno status→Recruiting
  • …and 361 more on the registry record
Oct 29, 2026
Primary completion
Nov 1, 2027→Nov 30, 2027
Oct 29, 2026
Study completion
Nov 1, 2027→Dec 30, 2027
Oct 29, 2026
Site contacts
Changed at 363 sites. See the sites
Show 363 sites
  • Anchorage Associates in Radiation Medicine · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Alaska Breast Care and Surgery LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Alaska Oncology and Hematology LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Alaska Women's Cancer Care · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Katmai Oncology Group · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Providence Alaska Medical Center · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Fairbanks Memorial Hospital · Fairbanks, United StatesContact added V•••@foundationhealth.org · •••3043Contact added (no phone or email listed)
  • Kingman Regional Medical Center · Kingman, United StatesContact added r•••@sncrf.org · •••0013Contact added (no phone or email listed)
  • Mercy Hospital Fort Smith · Fort Smith, United StatesContact added •••9373Contact added (no phone or email listed)
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, United StatesContact added E•••@bmhcc.org · •••7066Contact added (no phone or email listed)
  • CARTI Cancer Center · Little Rock, United StatesContact added R•••@carti.com · •••4199Contact added (no phone or email listed)
  • PCR Oncology · Arroyo Grande, United StatesContact added r•••@sncrf.org · •••0013Contact added (no phone or email listed)
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesContact added N•••@providence.org · •••4793Contact added (no phone or email listed)
  • Contra Costa Regional Medical Center · Martinez, United StatesContact added •••5400Contact added (no phone or email listed)
  • Providence Queen of The Valley · Napa, United StatesContact added •••3830Contact added (no phone or email listed)
  • Providence Medical Foundation - Santa Rosa · Santa Rosa, United StatesContact added •••3830Contact added (no phone or email listed)
  • Providence Santa Rosa Memorial Hospital · Santa Rosa, United StatesContact added •••3830Contact added (no phone or email listed)
  • BASS Medical Group - Lennon · Walnut Creek, United StatesContact added b•••@bassmedicalgroup.com · •••7636Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers-Aurora · Aurora, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Boulder Community Foothills Hospital · Boulder, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers-Boulder · Boulder, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers - Centennial · Centennial, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • The Women's Imaging Center · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Colorado Blood Cancer Institute · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Presbyterian - Saint Lukes Medical Center - Health One · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers-Midtown · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers-Rose · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers - Swedish · Englewood, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • The Melanoma and Skin Cancer Institute · Englewood, United StatesContact added r•••@theskincancerinstitute.com · •••8091Contact added (no phone or email listed)
  • Rocky Mountain Cancer Centers-Lakewood · Lakewood, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
  • …and 333 more sites
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Recruiting
    391 sites changed recruiting status (363 now recruiting, 27 now suspended, …)
    Show 391 sites
    • Anchorage Associates in Radiation Medicine · Anchorage, United Statesno status→Recruiting
    • Alaska Breast Care and Surgery LLC · Anchorage, United Statesno status→Recruiting
    • Alaska Oncology and Hematology LLC · Anchorage, United Statesno status→Recruiting
    • Alaska Women's Cancer Care · Anchorage, United Statesno status→Recruiting
    • Katmai Oncology Group · Anchorage, United Statesno status→Recruiting
    • Providence Alaska Medical Center · Anchorage, United Statesno status→Recruiting
    • Fairbanks Memorial Hospital · Fairbanks, United Statesno status→Recruiting
    • Kingman Regional Medical Center · Kingman, United Statesno status→Recruiting
    • Mercy Hospital Fort Smith · Fort Smith, United Statesno status→Recruiting
    • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, United Statesno status→Recruiting
    • CARTI Cancer Center · Little Rock, United Statesno status→Recruiting
    • PCR Oncology · Arroyo Grande, United Statesno status→Recruiting
    • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United Statesno status→Recruiting
    • Contra Costa Regional Medical Center · Martinez, United Statesno status→Recruiting
    • Providence Queen of The Valley · Napa, United Statesno status→Recruiting
    • Providence Medical Foundation - Santa Rosa · Santa Rosa, United Statesno status→Recruiting
    • Providence Santa Rosa Memorial Hospital · Santa Rosa, United Statesno status→Recruiting
    • BASS Medical Group - Lennon · Walnut Creek, United Statesno status→Recruiting
    • Rocky Mountain Cancer Centers-Aurora · Aurora, United Statesno status→Recruiting
    • Boulder Community Foothills Hospital · Boulder, United Statesno status→Recruiting
    • Rocky Mountain Cancer Centers-Boulder · Boulder, United Statesno status→Recruiting
    • Rocky Mountain Cancer Centers - Centennial · Centennial, United Statesno status→Recruiting
    • The Women's Imaging Center · Denver, United Statesno status→Recruiting
    • Colorado Blood Cancer Institute · Denver, United Statesno status→Recruiting
    • Presbyterian - Saint Lukes Medical Center - Health One · Denver, United Statesno status→Recruiting
    • Rocky Mountain Cancer Centers-Midtown · Denver, United Statesno status→Recruiting
    • Rocky Mountain Cancer Centers-Rose · Denver, United Statesno status→Recruiting
    • Mountain Blue Cancer Care Center - Swedish · Englewood, United Statesno status→Suspended
    • Rocky Mountain Cancer Centers - Swedish · Englewood, United Statesno status→Recruiting
    • The Melanoma and Skin Cancer Institute · Englewood, United Statesno status→Recruiting
    • …and 361 more on the registry record
    Primary completion Nov 1, 2027→Nov 30, 2027
    Study completion Nov 1, 2027→Dec 30, 2027
    Site contacts Changed at 363 sites. See the sites
    Show 363 sites
    • Anchorage Associates in Radiation Medicine · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Alaska Breast Care and Surgery LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Alaska Oncology and Hematology LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Alaska Women's Cancer Care · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Katmai Oncology Group · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Providence Alaska Medical Center · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Fairbanks Memorial Hospital · Fairbanks, United StatesContact added V•••@foundationhealth.org · •••3043Contact added (no phone or email listed)
    • Kingman Regional Medical Center · Kingman, United StatesContact added r•••@sncrf.org · •••0013Contact added (no phone or email listed)
    • Mercy Hospital Fort Smith · Fort Smith, United StatesContact added •••9373Contact added (no phone or email listed)
    • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, United StatesContact added E•••@bmhcc.org · •••7066Contact added (no phone or email listed)
    • CARTI Cancer Center · Little Rock, United StatesContact added R•••@carti.com · •••4199Contact added (no phone or email listed)
    • PCR Oncology · Arroyo Grande, United StatesContact added r•••@sncrf.org · •••0013Contact added (no phone or email listed)
    • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesContact added N•••@providence.org · •••4793Contact added (no phone or email listed)
    • Contra Costa Regional Medical Center · Martinez, United StatesContact added •••5400Contact added (no phone or email listed)
    • Providence Queen of The Valley · Napa, United StatesContact added •••3830Contact added (no phone or email listed)
    • Providence Medical Foundation - Santa Rosa · Santa Rosa, United StatesContact added •••3830Contact added (no phone or email listed)
    • Providence Santa Rosa Memorial Hospital · Santa Rosa, United StatesContact added •••3830Contact added (no phone or email listed)
    • BASS Medical Group - Lennon · Walnut Creek, United StatesContact added b•••@bassmedicalgroup.com · •••7636Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers-Aurora · Aurora, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Boulder Community Foothills Hospital · Boulder, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers-Boulder · Boulder, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers - Centennial · Centennial, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • The Women's Imaging Center · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Colorado Blood Cancer Institute · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Presbyterian - Saint Lukes Medical Center - Health One · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers-Midtown · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers-Rose · Denver, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers - Swedish · Englewood, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • The Melanoma and Skin Cancer Institute · Englewood, United StatesContact added r•••@theskincancerinstitute.com · •••8091Contact added (no phone or email listed)
    • Rocky Mountain Cancer Centers-Lakewood · Lakewood, United StatesContact added i•••@westernstatesncorp.org · •••2663Contact added (no phone or email listed)
    • …and 333 more sites
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06295367
Lead sponsor
ECOG-ACRIN Cancer Research Group
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Apr 10, 2024
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Gelareh Sadigh
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

ECOG-ACRIN Cancer Research Group →

Start the discussion